Bevacizumab biosimilar - Alteogen/CristaliaAlternative Names: Bevacizumab biosimilar - Alteogen
Latest Information Update: 22 May 2015
At a glance
- Originator Alteogen
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 22 May 2015 Discontinued - Preclinical for Cancer in South Korea (IV)